RE: Treatment of respiratory viral infections through inhalation therapeutics15 Oct 2022 09:59
"Recently inhalable formulation of interferon-ß-1a (SNG001) completed a phase 3 clinical trial (SPRINTER) in 623 hospitalized Covid-19 patients suffering from SARS-CoV-2. SNG001, a pH neutral nebuliser solution of interferon-ß-1a was given via inhalation using ultra device nebuliser at a dose of 15.6 MIU once daily for up to 14 days. Unfortunately, the study failed to show statistically significant benefits for its prespecified endpoints i.e., time to discharge from hospital and recovery. However, there was a reduction in relative risk of progression to severe disease or death within 35 days. This finding provides a strong clinical rationale for additional clinical trials [86,87]."